Bone strengthening drug for breast cancer with osteoporosis
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called romosozumab, which may help strengthen bones and reduce fractures in people with breast cancer that has spread to the bones and who also have osteoporosis. If you are on hormone therapy and have weak bones, this could help protect your bones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have breast cancer that is hormone-receptor positive (HR+) and has spread to the bones.
- You are currently receiving hormone therapy (with or without other targeted drugs).
- You have been diagnosed with osteoporosis or have had a fragility fracture (like a broken hip or spine) due to weak bones.
- You have not been previously treated with bone-strengthening drugs like bisphosphonates (e.g., zoledronic acid) or denosumab for bone disease.
- Your blood calcium and vitamin D levels are within normal range (or can be corrected with supplements).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
This study tests a combination of two bone-building drugs (romosozumab and teriparatide) in postmenopausal women with osteoporosis who are at high risk for fractures. The goal is to see if the combination strengthens bones faster and better than either drug alone.
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
This study looks at what changes in the body after starting romosozumab (an osteoporosis treatment) in postmenopausal women at higher risk for fractures. Researchers want to understand the treatment’s “mechanism,” which may help improve future osteoporosis care.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This study tests whether taking two osteoporosis medicines together (romosozumab and denosumab) can help prevent more broken bones in women after menopause who have already had several fractures. It may be a good option if you have weak bones and want to lower your risk of future breaks.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.